Buparlisib (BKM120) is a pan-class I PI3K inhibitor that showed modest efficacy and was tolerable in advanced acute leukemias (12 acute myeloid leukemia, 1 acute lymphoblastic leukemia, and 1 mixed phenotype leukemia) [94]. This evidence concerns the gene PIK3CA and acute myeloid leukemia.